119
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer: Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim
155
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma: Ratain MJ, Eisen T. Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai A, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, X